Accuray（ARAY）株式概要アキュレイ・インコーポレイテッドは、米国、カナダ、中南米、アジア、オーストラリア、ニュージーランド、ヨーロッパ、中東、インド、アフリカ、日本、中国で、腫瘍治療のための放射線手術および放射線治療システムの設計、開発、製造、販売に従事しています。 詳細ARAY ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬同業他社や業界と比較して、良好な取引価格 リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化が進んだ 現在は利益が出ておらず、今後3年間で利益が出る見込みはない 意味のある時価総額がありません ( $37M )すべてのリスクチェックを見るARAY Community Fair Values Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN87.7% undervaluedAnalystHighTarget•3mo agoFuture Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access2200AN81.3% undervaluedAnalystLowTarget•3mo agoService Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business1600AN90.3% undervaluedAnalystConsensusTarget•5mo agoRising Precision Radiotherapy Demand Will Support Stronger Long Term Earnings Power3601Top Analyst NarrativesAN87.7% undervaluedAnalystHighTarget•3mo agoFuture Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access2200AN81.3% undervaluedAnalystLowTarget•3mo agoService Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business1600AN90.3% undervaluedAnalystConsensusTarget•5mo agoRising Precision Radiotherapy Demand Will Support Stronger Long Term Earnings Power3601View all narrativesAccuray Incorporated 競合他社Milestone ScientificSymbol: NYSEAM:MLSSMarket cap: US$33.9mVasoSymbol: OTCPK:VASOMarket cap: US$40.1mCytosorbentsSymbol: NasdaqCM:CTSOMarket cap: US$28.9mSensus HealthcareSymbol: NasdaqCM:SRTSMarket cap: US$52.5m価格と性能株価の高値、安値、推移の概要Accuray過去の株価現在の株価US$0.3752週高値US$2.1052週安値US$0.25ベータ1.431ヶ月の変化-19.42%3ヶ月変化-37.58%1年変化-77.16%3年間の変化-89.62%5年間の変化-91.19%IPOからの変化-98.68%最新ニュースMajor Estimate Revision • May 13Consensus EPS estimates fall by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$443.2m to US$406.8m. Losses expected to increase from US$0.28 per share to US$0.38. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$2.53 to US$0.35. Share price fell 37% to US$0.30 over the past week.分析記事 • May 13Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) EstimatesToday is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...Breakeven Date Change • May 11No longer forecast to breakevenThe 2 analysts covering Accuray no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2028. New consensus forecast suggests the company will make a loss of US$17.3m in 2028.お知らせ • Apr 23Accuray Incorporated to Report Q3, 2026 Results on May 06, 2026Accuray Incorporated announced that they will report Q3, 2026 results on May 06, 2026お知らせ • Apr 07Accuray Incorporated Appoints Paul Miele As Senior Vice President And Chief Commercial Officer, Effective April 6, 2026Accuray Incorporated announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as Business Unit Leader and General Manager for the MONARCH robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical. As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence.新しいナラティブ • Feb 21Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care AccessCatalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?最新情報をもっと見るRecent updatesMajor Estimate Revision • May 13Consensus EPS estimates fall by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$443.2m to US$406.8m. Losses expected to increase from US$0.28 per share to US$0.38. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$2.53 to US$0.35. Share price fell 37% to US$0.30 over the past week.分析記事 • May 13Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) EstimatesToday is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...Breakeven Date Change • May 11No longer forecast to breakevenThe 2 analysts covering Accuray no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2028. New consensus forecast suggests the company will make a loss of US$17.3m in 2028.お知らせ • Apr 23Accuray Incorporated to Report Q3, 2026 Results on May 06, 2026Accuray Incorporated announced that they will report Q3, 2026 results on May 06, 2026お知らせ • Apr 07Accuray Incorporated Appoints Paul Miele As Senior Vice President And Chief Commercial Officer, Effective April 6, 2026Accuray Incorporated announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as Business Unit Leader and General Manager for the MONARCH robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical. As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence.新しいナラティブ • Feb 21Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care AccessCatalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?お知らせ • Feb 10Accuray Incorporated announced delayed 10-Q filingOn 02/09/2026, Accuray Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 07Accuray Incorporated Receives Notice of Non-Compliance with Nasdaq Bid Price RuleOn February 2, 2026, Accuray Incorporated (the Company) received a notice from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “ARAY” at this time. Nasdaq has provided the Company with a 180 calendar days compliance period (the “Compliance Period”), or until August 3, 2026, in which to regain compliance with the Bid Price Rule. In order to regain compliance with Nasdaq’s Bid Price Rule, shares of the Company’s common stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the Compliance Period, unless the Nasdaq Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). In the event that the Company does not regain compliance in the Compliance Period, the Company may be eligible for an additional 180 calendar days (the “Second Compliance Period”) pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(i) by transferring to the Nasdaq Capital Market. To qualify for the Second Compliance Period, the Company would need to submit a transfer application and pay an application fee. In addition, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the deficiency during the Second Compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting. There can be no assurance that the Company will be eligible for the Second Compliance Period, if applicable, or that the Nasdaq Staff would grant the Company’s request for continued listing subsequent to any delisting notification. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with the Bid Price Rule. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq continued listing requirements.分析記事 • Feb 06The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...Seeking Alpha • Feb 06Groundhog Day Once Again, As Accuray Misses And LowersSummary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha新しいナラティブ • Feb 06Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier BusinessCatalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?Reported Earnings • Feb 05Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: US$0.11 loss per share (down from US$0.025 profit in 2Q 2025). Revenue: US$102.2m (down 12% from 2Q 2025). Net loss: US$13.8m (down US$16.3m from profit in 2Q 2025). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 05Accuray Incorporated Updates Earnings Guidance for the Fiscal Year 2026Accuray Incorporated update earnings guidance for the fiscal year 2026. For the period, the company expects total net revenue in the range of $440 million to $450 million.お知らせ • Jan 22Accuray Incorporated to Report Q2, 2026 Results on Feb 04, 2026Accuray Incorporated announced that they will report Q2, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 04, 2026お知らせ • Jan 21Accuray Incorporated Announces Resignation of Sandeep Chalke as Senior Vice President and Chief Commercial Officer, Effective March 31, 2026Accuray Incorporated announced that on January 15, 2026, Sandeep Chalke provided notice of his intent to resign from his position as Senior Vice President and Chief Commercial Officer of the company, with the resignation effective on March 31, 2026. Mr. Chalke’s resignation was not a result of any disagreement with the Company or the Board of Directors of the Company, or any matter relating to the Company’s operations, policies or practices.お知らせ • Jan 01Accuray Incorporated Announces Retirement of Byron C. Scott as Class III Director and Including All Committees, Effective December 31, 2025On December 27, 2025, Byron C. Scott, a Class II director of Accuray Incorporated, informed the company’s Board of Directors that he will retire from the Board, including all committees of the Board on which he sits, effective December 31, 2025. The decision by Mr. Scott to retire from the Board is not due to any disagreement with the Company or the Board, or any matter relating to the Company’s operations, policies or practices.New Risk • Dec 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$14m net loss in 2 years). Market cap is less than US$100m (US$97.0m market cap).分析記事 • Dec 20Accuray (NASDAQ:ARAY) May Have Issues Allocating Its CapitalIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...分析記事 • Dec 02Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% PoundingThe Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...分析記事 • Nov 27Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Nov 14Consensus EPS estimates fall by 929%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$475.2m to US$466.7m. Losses expected to increase from US$0.035 per share to US$0.36. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$4.75 to US$3.88. Share price fell 11% to US$1.04 over the past week.Breakeven Date Change • Nov 14Forecast breakeven date pushed back to 2028The 2 analysts covering Accuray previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$8.60m in 2028. Average annual earnings growth of 42% is required to achieve expected profit on schedule.Reported Earnings • Nov 06First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.18 loss per share (further deteriorated from US$0.039 loss in 1Q 2025). Revenue: US$93.9m (down 7.5% from 1Q 2025). Net loss: US$21.7m (loss widened 448% from 1Q 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Nov 06Accuray Incorporated Reaffirms Earnings Guidance for the Fiscal Year 2026Accuray Incorporated reaffirmed earnings guidance for the fiscal year 2026. The company expects total net revenue in the range of $471 million to $485 million.お知らせ • Oct 29Accuray Incorporated to Report Q1, 2026 Results on Nov 05, 2025Accuray Incorporated announced that they will report Q1, 2026 results on Nov 05, 2025お知らせ • Oct 21+ 1 more updateAccuray Incorporated Announces Executive ChangesAccuray Incorporated announced that on October 20, 2025, the board appointed Stephen La Neve as President effective as of October 20, 2025. Mr. La Neve was also appointed to the Board as a Class III director with his initial term ending at the Company’s 2027 annual meeting of stockholders. Mr. La Neve will succeed Suzanne Winter, the Company’s President who has resigned from her position as President and has resigned as a member of the Board, effective October 19, 2025. Ms. Winter will continue to serve as an advisor through November 30, 2025 to provide an orderly transition. Mr. La Neve, 66, most recently served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and, previously, Globus Medical Japan K.K., a provider of musculoskeletal device solutions, from 2019 to 2024. From 2015 to 2019, Mr. La Neve was CEO of Bone Biologics Corporation, a medical device company focused on bone regeneration. He also served as a member of the board of directors of Bone Biologics Corporation until December 2022. Prior to that, Mr. La Neve served as CEO of Life Science Enterprises Inc., an early-stage biomaterials company spun out from ETEX Corporation, from 2014 to 2015, and CEO of ETEX Corporation, an advanced biomaterials company, from 2014 until Zimmer Holdings Inc. acquired the business of ETEX Holdings Inc. late in 2014. Prior to that role, Mr. La Neve was CEO and a member of the board of directors at SkelRegen, LLC, Global President of Becton Dickinson Preanalytical Systems, Global President of Medtronic Spine and Biologics Inc., as well as President of Medtronic Japan. Early in his career, Mr. La Neve served in various commercial roles for three diagnostics companies: Becton Dickinson, Roche and EM Diagnostic Systems, domestically and internationally. He has served as a board member for several healthcare companies in the medical device and diagnostic segments, currently including Insight Medbotics, a company developing MRI guided robotics for interventional oncology. Mr. La Neve holds a B.S. in Health Planning and Administration from the Pennsylvania State University and an MBA from West Chester University. He is a member of Omicron Delta Epsilon, an international honor society recognizing academic excellence and achievements in economics.分析記事 • Oct 10Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share PriceAccuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...お知らせ • Oct 08Accuray Incorporated Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® SystemAccuray Incorporated announced that 5D Clinics has treated the first patients in the city of Melbourne, Australia, using the CyberKnife S7™ System. 5D Clinics and joint venture partner Icon Group will open and operate CyberKnife System centers across Australia, with the goal of making it easier for cancer patients to obtain precision robotic stereotactic body radiation therapy (SBRT) and stereotactic radio surgery (SRS) treatments closer to home. With an initial focus on the East Coast of Australia, the new center in Melbourne is the first to be managed by the J. The number of new cancer cases diagnosed in Australia is projected to grow from 212,332 in 2022 to 318,285 in 20451, a nearly 50% increase. The rise in patient diagnoses reinforces the need for innovative new treatment options, such as the CyberKnife System, that can effectively manage the disease while improving the care journey and its impact on patients' quality of life. The CyberKnife S7™ System combines speed, precision, and artificial intelligence (AI) to track and automatically adapt for movement during treatment, delivering the radiation dose directly to the target anywhere in the body. The precision and accuracy of the system enables medical teams to deliver very high doses of radiation in a few days versus conventional fractionation which often require 30-40 sessions. The entire CyberKnife System procedure is typically completed in just 1 to 5 out-patient sessions, making radiation treatments delivered with sub-millimeter precision and accuracy an option for people unable to travel a month or more for care. alphaXRT is the exclusive distributor, installer and training partner for the Accuray CyberKnife and TomoTherapy® platform portfolios in Australasia. In close cooperation with the Accuray global team, 5D Clinics and Icon Group, they supported the entire CyberKnife System installation process through the first patient treatment, and will provide ongoing service and assistance.お知らせ • Oct 02Accuray Incorporated, Annual General Meeting, Nov 13, 2025Accuray Incorporated, Annual General Meeting, Nov 13, 2025.お知らせ • Sep 26Accuray Incorporated Launches All-In-One Radiotherapy Solution with Advanced Capabilities Designed to Set A New Standard in Cancer CareAccuray Incorporated announced that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™? Solution. Initially for the U.S. market, the new Accuray technology is not just a system, it's a solution, comprised of a comprehensive tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy. The Accuray Stellar solution, a configuration of the Radixact®? Treatment Delivery System, will be featured at Accuray booth #525 during the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California, September 28 - 30, 2025. Meeting attendees are invited to attend the U.S. unveiling at the company's booth on September 28, at 11:30 am PT. To broaden the reach of transformative cancer care, Accuray Stellar easily integrates with the company's proprietary software and hardware solutions -- and vendor partner technologies -- expanding the range of available radiation delivery options and streamlining the treatment workflow for each patient. With Accuray Stellar, clinicians have access to a solution capable of the full range of delivery modalities, from image-guided radiation therapy (IMRT) to stereotactic body radiation therapy (SBRT) treatments and surface-guided ration therapy (SGRT), to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow radiation. Accuray Stellar provides a unique option for accurately delivering radiation while correcting for changes in the size or shape of the tumor, and patient or tumor movement, that can occur while patients undergo care. The solution offers a versatile and simplified path to adaptive radiotherapy developed to provide the foundation for adaptive care that can evolve with each patient's needs. The adaptive suite ranges from real-time motion tracking and correction, with Synchrony®? technology, to offline adaptive protocols featuring PreciseART®?, as well as an online-adaptive ready interface (a prerequisite for OART), providing the foundation for adaptive care that evolves with each patient's needs. Medical care teams can also leverage one of the company's latest innovations, Adapt LTE powered by Accuray Cenos, only available on Accuray Stellar.Price Target Changed • Sep 23Price target decreased by 8.1% to US$4.75Down from US$5.17, the current price target is an average from 2 analysts. New target price is 176% above last closing price of US$1.72. Stock is down 2.8% over the past year. The company is forecast to post a net loss per share of US$0.035 next year compared to a net loss per share of US$0.015 last year.お知らせ • Aug 23Accuray Incorporated Announces Management ResignationOn August 19, 2025, Robert C. Kill, a Class I director of Accuray Incorporated (the Company"), informed the Company's Board of Directors (the Board") of his intention not to stand for re-election at the Company's 2025 annual meeting of stockholders to be held in November 2025 (the Annual Meeting"). Mr. Kill will continue to serve as a director and member of the Compensation Committee of the Board until the conclusion of the Annual Meeting. The decision by Mr. Kill to not stand for re-election is not due to any disagreement with the Company or the Board, or any matter relating to the Company's operations, policies or practices. On August 19, 2025, Jesse Chew provided the Company with notice of his intent to resign from his position as Senior Vice President, Chief Legal Officer and Corporate Secretary of the Company, which resignation will be effective on September 19, 2025. Mr. Chew has agreed to consult with the Company through December 31, 2025, subject to terms to be agreed upon between the Company and Mr. Chew. Mr. Chew's resignation was not a result of any disagreement with the Company or the Board, or any matter relating to the Company's operations, policies or practices.Major Estimate Revision • Aug 20Consensus estimates of losses per share improve by 36%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$445.1m to US$475.8m. EPS estimate increased from -US$0.047 per share to -US$0.03 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target up from US$5.17 to US$5.50. Share price was steady at US$1.51 over the past week.Reported Earnings • Aug 14Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$0.015 loss per share (improved from US$0.16 loss in FY 2024). Revenue: US$458.5m (up 2.7% from FY 2024). Net loss: US$1.59m (loss narrowed 90% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 3.8% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Aug 14Accuray Incorporated Provides Earnings Guidance for Fiscal Year Ending June 30, 2026Accuray Incorporated provided earnings guidance for fiscal year ending June 30, 2026. For the year, the company expects total net revenue in the range of $471 million to $485 million. GAAP net loss expected to be $12,000,000 to $8,000,000.分析記事 • Aug 13Returns At Accuray (NASDAQ:ARAY) Are On The Way UpIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...お知らせ • Jul 31Accuray Incorporated to Report Q4, 2025 Results on Aug 13, 2025Accuray Incorporated announced that they will report Q4, 2025 results on Aug 13, 2025分析記事 • Jun 28Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...Recent Insider Transactions • Jun 18Independent Chairman of the Board recently bought US$62k worth of stockOn the 13th of June, Joseph Whitters bought around 50k shares on-market at roughly US$1.25 per share. This transaction amounted to 8.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.Price Target Changed • Jun 12Price target decreased by 8.1% to US$5.17Down from US$5.63, the current price target is an average from 3 analysts. New target price is 313% above last closing price of US$1.25. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.0033 next year compared to a net loss per share of US$0.16 last year.お知らせ • Jun 06Accuray Incorporated Appoints Steven F. Mayer to Its BoardAccuray Incorporated has entered into a governance agreement with TCW Asset Management Company LLC, which provides for the appointment of one director to Accuray's Board of Directors. TCW has designated, and Accuray has appointed, Steven F. Mayer to its Board. Mr. Mayer serves as Chairman of the Operations Advisory Council and senior advisor to the private credit group of TCW. Previously, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, and Co-Head of Global Private Equity and Chairman of the Investment Committee of Cerberus Capital Management, L.P., a private investment firm with approximately $60 billion of capital under management. He has extensive governance experience, having served as a member of the Boards of Directors of more than 30 other public and private companies spanning a range of industries, including medical technology and biotherapeutics.Price Target Changed • May 07Price target decreased by 8.2% to US$5.63Down from US$6.13, the current price target is an average from 4 analysts. New target price is 314% above last closing price of US$1.36. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.0075 next year compared to a net loss per share of US$0.16 last year.お知らせ • May 02Accuray Incorporated Provides Earnings Guidance for the Fourth Quarter of 2025Accuray Incorporated provided earnings guidance for the fourth quarter of 2025. For the quarter, the company expects revenues to be in the range of $121 million to $129 million.New Risk • May 01New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Large one-off items impacting financial results.お知らせ • May 01Accuray Incorporated Provides Earnings Guidance for the Full Year 2025Accuray Incorporated provided earnings guidance for the full year 2025. For the period, the company's Total revenue is expected in the range of $452 millionto $460 million.Board Change • May 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Rob Kill was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 17Accuray Incorporated to Report Q3, 2025 Results on Apr 30, 2025Accuray Incorporated announced that they will report Q3, 2025 results on Apr 30, 2025分析記事 • Apr 04Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share PriceWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...お知らせ • Apr 03Accuray Incorporated Announces New Data on the Clinical Use of the CyberKnife SystemAccuray Incorporated announced that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States1. The studies, involving the delivery of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), were presented at the recent 2025 Radiosurgery Society (RSS) Scientific Meeting in Tucson, Arizona. SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destruction) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony® adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion. The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tumors like vestibular schwannoma or managing complex conditions such as spinal metastases and trigeminal neuralgia, the common thread is the need for precise, highly targeted radiation delivery -- a hallmark of the CyberKnife System; These new data not only reinforce its value in central nervous system treatments but also add to the growing body of evidence supporting its role in improving both the quality and longevity of patients' lives; 25-year data were reported for patients in a single institution study retrospectively evaluating SRS for the treatment of VS (also known as acoustic neuroma) using the CyberKnife System. A non-cancerous, usually slow-growing brain tumor, VS can cause hearing loss, ringing in the ear, and dizziness or loss of balance. Pain improved or disappeared in 90% of those evaluated and only 3% developed paresthesia - a sensation of tingling, "pins and needs" or numbness - considered bothersome. Data indicate radiosurgery provides an option for a patient population that may have limited choices because health issues preclude surgery or they are unresponsive to medication4. An evaluation of SRS for occipital condyle metastasis (OCM) using the CyberKnife system found the treatment offers significant pain relief, excellent local control rates and improvement in neurological symptoms. A 93.8% local tumor control rate was achieved over three years.分析記事 • Mar 11Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price DropAccuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...Reported Earnings • Feb 06Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.025 (up from US$0.098 loss in 2Q 2024). Revenue: US$116.2m (up 8.3% from 2Q 2024). Net income: US$2.54m (up US$12.2m from 2Q 2024). Profit margin: 2.2% (up from net loss in 2Q 2024). Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 06Accuray Incorporated Raises Earnings Guidance for the Year 2025Accuray Incorporated raising earnings guidance for the year 2025. For the year, the company expects total revenue is expected in the range of $463 million to $475 million.お知らせ • Jan 23Accuray Incorporated to Report Q2, 2025 Results on Feb 05, 2025Accuray Incorporated announced that they will report Q2, 2025 results on Feb 05, 2025お知らせ • Jan 21Accuray Incorporated Appoints Leonel Peralta as Senior Vice President, Chief Operations Officer, Effective February 3, 2025Accuray Incorporated announced that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has a proven work history in driving growth while improving productivity and bringing more than 25 years of leadership experience in supply chain, business process improvement, and manufacturing optimization. Most recently, Leonel was Vice President, Head of Global Operations for the ultrasound division at Siemens Healthineers where he led the transformation of supply chain processes, the manufacturing footprint and the organizational structure, for the ultrasound business unit within the company. Prior to this, Leonel held executive management positions at Medtronic Diabetes, Hill-Rom (Baxter), KCI Medical (3M), and GE Healthcare. Under his leadership his teams executed corporate growth and financial objectives, significantly reduced inventory levels, and transformed sourcing and supply chain operations.分析記事 • Jan 18Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For GrowthAccuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...お知らせ • Jan 15Accuray Incorporated Announces China National Medical Products Administration Approval of Radixact SynC and CyberKnife S7 SystemsAccuray Incorporated announced that the company's Radixact SynC System and CyberKnife S7 System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform and the introduction of the Radixact SynC System marks the first approval in the country for the ClearRT kVCT imaging and Synchrony real-time adaptive delivery technology on the Radixact System. The Radixact SynC and CyberKnife S7 Systems are designed to improve the radiation treatment experience while making high precision care available for more patients. Radixact SynC System: Cancer Treatment that Revolves Around the Patient: The Radixact SynC System's helical design enables the delivery of precise doses of radiation continuously from multiple 360-degree rotations around the patient, providing greater control of the radiation dose so it conforms precisely to the tumor and minimizes dose to healthy tissue. The Radixact SynC System is currently the only helical delivery device in China with Synchrony real-time target tracking and correction technology. The addition of Synchrony to the Radixact System is designed to facilitate more precise delivery of radiation to tumors that move as a result of bodily processes or patient movement. The Accuray proprietary Synchrony technology is unique in using image guidance during radiation treatment delivery to detect motion and automatically adapt and synchronize the radiation beam in real-time with the movement of the target. ClearRT is a helical kVCT fan-beam integrated imaging solution for the Radixact System, providing clinicians with an option for easily, quickly and cost effectively acquiring diagnostic-like quality CT images. These images enable high confidence in the patient set-up and registration steps that form the basis of radiation therapy treatment delivery and monitoring and are key to the successful treatment of organ-confined tumors, locally advanced tumors and metastatic tumors. The CyberKnife S7 System: Robotic Precision that Makes Treatment Possible in just 1 to 5 Out-Patient Sessions: The new generation CyberKnife platform delivers the extremely precise radiation treatments clinicians have come to expect with the system, combined with the speed they need to support their busy practices. The CyberKnife S7 System is a robotic, non-invasive radiosurgery device capable of treating cancerous and benign tumors throughout the body with sub-millimetric accuracy in as little as 15 minutes, enabling medical care teams to provide highly precise radiation treatments to more patients, every day. The precision and accuracy of the CyberKnife System enables clinical teams to deliver ultra-hypofractionated radiation therapy ? very high doses of precisely targeted radiation are delivered in a few days versus conventional fractionation where treatments often require 30-40 sessions. The entire procedure with the CyberKnife System is typically completed in just 1 to 5 out-patient sessions, enabling those people who are unable to travel a month or more for care to receive radiation therapy treatments.Seeking Alpha • Jan 07Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking Alpha分析記事 • Dec 19Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Dec 14Accuray Incorporated Announces the Departure of Michael Hoge as Senior Vice President, Global Operations, Effective January 6, 2025On December 6, 2024, Accuray Incorporated and Michael Hoge, the company’s Senior Vice President, Global Operations, mutually agreed to terms pursuant to which Mr. Hoge will depart the Company as an employee effective January 6, 2025. Mr. Hoge’s departure is not the result of any dispute or disagreement with the Company, its board of directors, or its management, or any matter relating to the Company’s operations, policies or practices. The Company has initiated a comprehensive search process to identify Mr. Hoge’s successor.Seeking Alpha • Dec 05Accuray Incorporated: Cheap, But With CaveatsSummary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking Alphaお知らせ • Nov 28Accuray Incorporated Approves to Appoint Michael Murphy as the Principal Accounting Officer, Effective December 2, 2024Accuray Incorporated approved the appointed Michael Murphy, 45, as the Company’s principal accounting officer, effective December 2, 2024. Mr. Murphy joined the Company in October 2024 as Vice President, Corporate Controller. Previously, from February 2024 to October 2024, he served as Vice President, Chief Accounting Officer and Treasury at Duluth Trading Company, an American workwear and accessories company, where he also served as Interim Chief Financial Officer, Vice President and Chief Accounting Officer from September 2023 to February 2024, Vice President and Chief Accounting Officer from September 2019 to August 2023 and Corporate Controller from December 2018 to September 2019. Prior to that, he served as Chief Accounting Officer at First Business Financial Services Inc., a financial services company, from September 2015 to December 2018. Mr. Murphy began his career at KPMG LLP. Mr. Murphy received a Bachelor of Business Administration, Accounting and Finance as well as a Master of Accountancy, both from the University of Wisconsin-Madison.お知らせ • Nov 08Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025Accuray Incorporated raised financial guidance for the fiscal year ending June 30, 2025. For the year, the company’s total revenue is expected in the range of $462 million to $472 million; GAAP net loss expected in the range of $4,500,000 to $2,500,000.お知らせ • Oct 24Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024Accuray Incorporated announced that they will report Q1, 2025 results on Nov 06, 2024お知らせ • Oct 15Accuray Incorporated Announces CEO ChangesAccuray Incorporated announced that, effective as of October 15, 2024, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer. Sandeep Chalke, who has served as interim CEO during Ms. Winter's absence, will continue in his position as Senior Vice President and Chief Commercial Officer.お知らせ • Oct 07Accuray Incorporated, Annual General Meeting, Nov 21, 2024Accuray Incorporated, Annual General Meeting, Nov 21, 2024.お知らせ • Sep 17Accuray Incorporated announced delayed annual 10-K filingOn 09/16/2024, Accuray Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 04+ 1 more updateAccuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of AbsenceAccuray Incorporated announced that President Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an Executive Committee of the Board of Directors, consisting of Joseph Whitters, Chairman of the Accuray Board, and Anne Le Grand, Chair of the Science and Technology Committee, that will advise Mr. Chalke in his interim capacity. Mr. Chalke joined Accuray in May 2022 bringing more than 30 years of medical device expertise in commercialization, business development and operations. In his role at Accuray, he has responsibility for the global commercial function, including the organization's sales, service and operations teams.Seeking Alpha • Aug 18Accuray Remains A Perpetual 'Next Year Is Our Year' StorySummary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking AlphaBreakeven Date Change • Aug 16Forecast breakeven date pushed back to 2026The 4 analysts covering Accuray previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 73% to 2025. The company is expected to make a profit of US$12.4m in 2026. Average annual earnings growth of 137% is required to achieve expected profit on schedule.New Risk • Aug 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.6% increase in shares outstanding).Reported Earnings • Aug 15Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.16 loss per share (further deteriorated from US$0.098 loss in FY 2023). Revenue: US$446.6m (flat on FY 2023). Net loss: US$15.5m (loss widened 68% from FY 2023). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.お知らせ • Aug 15Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025Accuray Incorporated provided earnings guidance for the fiscal year 2025. For the year, total revenue is expected in the range of $460 million to $470 million.分析記事 • Aug 13Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching RevenuesAccuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...お知らせ • Aug 01Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024Accuray Incorporated announced that they will report Q4, 2024 results on Aug 14, 2024お知らせ • Jun 15Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products AdministrationAccuray Incorporated announced that the registration dossier for the AccurayPrecision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China. The Accuray Precision TPS was developed to facilitate the creation and adaptation of precise treatment plans in less time. The planning solution enables clinicians to routinely incorporate modifications to treatment planning into the course of treatment to account for changes in tumor size, shape and location – as well as subtle changes in the location of organs and other healthy tissue – thereby increasing treatment precision. The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue. The system is designed to enable medical care teams to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.Breakeven Date Change • Jun 06Forecast breakeven date pushed back to 2026The 4 analysts covering Accuray previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$15.5m in 2026. Average annual earnings growth of 123% is required to achieve expected profit on schedule.Recent Insider Transactions • Jun 02Independent Chairman of the Board recently bought US$156k worth of stockOn the 29th of May, Joseph Whitters bought around 100k shares on-market at roughly US$1.56 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.分析記事 • May 21Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price DropTo the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...お知らせ • May 11Accuray Incorporated Announces Executive Changes, Effective May 17, 2024On May 6, 2024, Gina Corradetti provided Accuray Incorporated with notice of her intent to resign from her position as Chief Accounting Officer and principal accounting officer, which resignation will be effective May 17, 2024, to pursue other opportunities. On May 9, 2024, the Company’s Board of Directors appointed Ali Pervaiz, the Company’s Senior Vice President, Chief Financial Officer, to serve as the Company’s interim principal accounting officer, effective May 17, 2024 until a permanent successor is appointed. Mr. Pervaiz, age 44, will continue to serve as the Company’s Senior Vice President and Chief Financial Officer, a position he has held since May 2022. Previously, Mr. Pervaiz served as the Company’s Vice President, Global Commercial Operations beginning August 2020. Prior to joining the Company, Mr. Pervaiz was with General Electric Healthcare (“GE Healthcare”), a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging business from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previously held business unit Chief Financial officer roles at GE Healthcare for the US Commercial Diagnostic Imaging Equipment and US Commercial Life Support Solutions businesses. Mr. Pervaiz received an M.B.A. from the University of Chicago Booth School of Business with focus on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.分析記事 • May 04Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest ResultsIt's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...Price Target Changed • May 03Price target decreased by 11% to US$7.75Down from US$8.75, the current price target is an average from 4 analysts. New target price is 378% above last closing price of US$1.62. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.098 last year.分析記事 • May 03Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...お知らせ • May 03Accuray Incorporated Provides Earnings Guidance for the Year 2024Accuray Incorporated provided earnings guidance for the year 2024. The company is adjusting its guidance for fiscal year 2024 as follows: Total revenue is expected in the range of $432 million to $437 million.Reported Earnings • May 02Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: US$0.064 loss per share (down from US$0.006 profit in 3Q 2023). Revenue: US$101.1m (down 14% from 3Q 2023). Net loss: US$6.34m (down US$6.94m from profit in 3Q 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • May 02Now 35% undervalued after recent price dropOver the last 90 days, the stock has fallen 38% to US$1.53. The fair value is estimated to be US$2.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Apr 26Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024Accuray Incorporated announced that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife®? and Radixact®? platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland. Accuray is a wellness focused organization, taking into account the patient's health and well-being throughout their treatment when prioritizing product enhancements. The solutions featured at ESTRO represent a few of the most recent innovations introduced over a 30 year history of invention and disruption that has led to new standards in care for the radiation therapy industry. The company invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases-- while making commonly treatable cases even easier--to meet the full spectrum of patient needs.お知らせ • Apr 19Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024Accuray Incorporated announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on May 01, 2024Seeking Alpha • Apr 07Accuray Getting Very Little Love Ahead Of A Coming Revenue RampSummary Despite management guidance that points to significant revenue acceleration in the next two quarters, Accuray shares have languished. Market skepticism can be tied in part to the company's track record - despite multiple efforts to improve its portfolio and go-to-market strategy, market share growth has been very modest. The company's entry into China's Type B market could be its last best chance to change the narrative - meaningful share in a $600M/year market should be transformative. Accuray faces tough competition from Varian and Elekta, but is focusing on upgrading its installed base, targeting selective vault share gain opportunities, and pursuing value-based opportunities in emerging markets. Accuray shares should trade closer to $4-$6, but Accuray must deliver on the potential of the Chinese market and establish new, higher, expectations for growth and margins. Read the full article on Seeking Alphaお知らせ • Mar 26Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife SystemAccuray Incorporated announced that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy - supporting the system's versatility and value to medical care teams. The CyberKnife System enables treatment of prostate cancer using a form of radiation therapy called stereotactic body radiation therapy (SBRT) - very precise, high doses of radiation are delivered over a shorter duration than traditional treatments. The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT. CyberKnife Platform for Prostate Cancer: The CyberKnife platform offers an effective treatment option for prostate tumors in 4-5 sessions, compared to conventional radiation therapy that usually requires approximately 30-40 sessions over 8-10 weeks. Data presented at the RSS meeting showed its ability to: Effectively treat high-risk disease while preserving quality of life. Study authors concluded, "At the 3-year follow-up mark, favorable biochemical control was achieved, and patients had largely recovered to near baseline urinary and bowel function. These findings underscore the potential of SBRT as a convenient treatment option for high-risk prostate cancer, offering promising outcomes and preserving patient quality of life. Provide a viable option with "a low incidence of short-term genitourinary (GU) and gastrointestinal (GI) toxicities" for reirradiation of locally recurrent prostate cancer. The prostate gland can move unpredictably throughout the course of treatment. In fact, the prostate has been documented to move as much as 10 mm in as little as 30 seconds due to normal patient bodily functions – such as filling of the bladder, gas in the bowel, or even slight patient movement during the procedure making the ability to track, detect and correct for motion critically important. The CyberKnife System, using advanced imaging and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery, with the Accuray proprietary Synchrony® technology, can track the tumor and continually verify its position, automatically correcting and adapting the radiation beam position for even the slightest movement. For example, if the prostate moves during treatment the CyberKnife® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time.New Risk • Feb 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Significant insider selling over the past 3 months (US$433k sold).分析記事 • Feb 03Is Accuray (NASDAQ:ARAY) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Feb 02Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: US$0.098 loss per share (further deteriorated from US$0.02 loss in 2Q 2023). Revenue: US$107.2m (down 6.6% from 2Q 2023). Net loss: US$9.62m (loss widened 413% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Breakeven Date Change • Feb 01The 3 analysts covering Accuray previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 45% to 2024. The company is expected to make a profit of US$14.8m in 2025. Average annual earnings growth of 1.1% is required to achieve expected profit on schedule.株主還元ARAYUS Medical EquipmentUS 市場7D31.1%0.3%2.5%1Y-77.2%-19.6%26.4%株主還元を見る業界別リターン: ARAY過去 1 年間で-19.6 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: ARAYは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。価格変動Is ARAY's price volatile compared to industry and market?ARAY volatilityARAY Average Weekly Movement21.8%Medical Equipment Industry Average Movement8.6%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: ARAYの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ARAYの 週次ボラティリティ は、過去 1 年間で13%から22%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1990990Steve LaNevewww.accuray.comアキュレイ・インコーポレイテッドは、米国、カナダ、中南米、アジア、オーストラリア、ニュージーランド、ヨーロッパ、中東、インド、アフリカ、日本、中国で、腫瘍治療のための放射線手術および放射線治療システムの設計、開発、製造、販売に従事している。同社はサイバーナイフ・プラットフォームを提供しており、脊椎やその近傍、乳房、腎臓、肝臓、肺、膵臓、前立腺など、脳以外の原発性・転移性腫瘍の治療に用いられるロボット定位放射線手術・定位体放射線治療システムである。また、トモセラピー・プラットフォームとして、放射線治療計画、提供、データ管理を統合し、臨床医が1日約50人の患者に超精密治療を提供できるようにするラディクサクト・システム、完全に統合された治療計画・データ管理システムであるiDMSデータ管理システム、治療計画・データ管理システムであるアキュレイ精密治療計画システムなどを提供している。さらに、契約後の顧客サポート、設置、トレーニング、その他の専門サービスも提供している。アキュレイ・インコーポレーテッドは主に、販売組織を通じて病院や独立型治療施設などの顧客に製品を直接販売するほか、米国では販売代理店やグループ購買組織を通じて顧客に販売し、海外では直接販売および代理店や販売代理店を通じて顧客に販売している。アキュレイ・インコーポレイテッドは1990年に設立され、ウィスコンシン州マディソンに本社を置いています。もっと見るAccuray Incorporated 基礎のまとめAccuray の収益と売上を時価総額と比較するとどうか。ARAY 基礎統計学時価総額US$36.51m収益（TTM）-US$46.13m売上高(TTM)US$428.57m0.1xP/Sレシオ-1.0xPER（株価収益率ARAY は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ARAY 損益計算書（TTM）収益US$428.57m売上原価US$313.22m売上総利益US$115.36mその他の費用US$161.49m収益-US$46.13m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.39グロス・マージン26.92%純利益率-10.76%有利子負債／自己資本比率348.1%ARAY の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 09:23終値2026/05/26 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Accuray Incorporated 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Neil ChatterjiB. Riley Securities, Inc.Marie ThibaultBTIGMichael GormanBTIG13 その他のアナリストを表示
Major Estimate Revision • May 13Consensus EPS estimates fall by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$443.2m to US$406.8m. Losses expected to increase from US$0.28 per share to US$0.38. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$2.53 to US$0.35. Share price fell 37% to US$0.30 over the past week.
分析記事 • May 13Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) EstimatesToday is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
Breakeven Date Change • May 11No longer forecast to breakevenThe 2 analysts covering Accuray no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2028. New consensus forecast suggests the company will make a loss of US$17.3m in 2028.
お知らせ • Apr 23Accuray Incorporated to Report Q3, 2026 Results on May 06, 2026Accuray Incorporated announced that they will report Q3, 2026 results on May 06, 2026
お知らせ • Apr 07Accuray Incorporated Appoints Paul Miele As Senior Vice President And Chief Commercial Officer, Effective April 6, 2026Accuray Incorporated announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as Business Unit Leader and General Manager for the MONARCH robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical. As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence.
新しいナラティブ • Feb 21Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care AccessCatalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?
Major Estimate Revision • May 13Consensus EPS estimates fall by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$443.2m to US$406.8m. Losses expected to increase from US$0.28 per share to US$0.38. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$2.53 to US$0.35. Share price fell 37% to US$0.30 over the past week.
分析記事 • May 13Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) EstimatesToday is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
Breakeven Date Change • May 11No longer forecast to breakevenThe 2 analysts covering Accuray no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2028. New consensus forecast suggests the company will make a loss of US$17.3m in 2028.
お知らせ • Apr 23Accuray Incorporated to Report Q3, 2026 Results on May 06, 2026Accuray Incorporated announced that they will report Q3, 2026 results on May 06, 2026
お知らせ • Apr 07Accuray Incorporated Appoints Paul Miele As Senior Vice President And Chief Commercial Officer, Effective April 6, 2026Accuray Incorporated announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as Business Unit Leader and General Manager for the MONARCH robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical. As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence.
新しいナラティブ • Feb 21Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care AccessCatalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?
お知らせ • Feb 10Accuray Incorporated announced delayed 10-Q filingOn 02/09/2026, Accuray Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 07Accuray Incorporated Receives Notice of Non-Compliance with Nasdaq Bid Price RuleOn February 2, 2026, Accuray Incorporated (the Company) received a notice from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “ARAY” at this time. Nasdaq has provided the Company with a 180 calendar days compliance period (the “Compliance Period”), or until August 3, 2026, in which to regain compliance with the Bid Price Rule. In order to regain compliance with Nasdaq’s Bid Price Rule, shares of the Company’s common stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the Compliance Period, unless the Nasdaq Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). In the event that the Company does not regain compliance in the Compliance Period, the Company may be eligible for an additional 180 calendar days (the “Second Compliance Period”) pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(i) by transferring to the Nasdaq Capital Market. To qualify for the Second Compliance Period, the Company would need to submit a transfer application and pay an application fee. In addition, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the deficiency during the Second Compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting. There can be no assurance that the Company will be eligible for the Second Compliance Period, if applicable, or that the Nasdaq Staff would grant the Company’s request for continued listing subsequent to any delisting notification. The Company is currently evaluating options to regain compliance and intends to timely regain compliance with the Bid Price Rule. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq continued listing requirements.
分析記事 • Feb 06The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...
Seeking Alpha • Feb 06Groundhog Day Once Again, As Accuray Misses And LowersSummary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha
新しいナラティブ • Feb 06Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier BusinessCatalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?
Reported Earnings • Feb 05Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: US$0.11 loss per share (down from US$0.025 profit in 2Q 2025). Revenue: US$102.2m (down 12% from 2Q 2025). Net loss: US$13.8m (down US$16.3m from profit in 2Q 2025). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 05Accuray Incorporated Updates Earnings Guidance for the Fiscal Year 2026Accuray Incorporated update earnings guidance for the fiscal year 2026. For the period, the company expects total net revenue in the range of $440 million to $450 million.
お知らせ • Jan 22Accuray Incorporated to Report Q2, 2026 Results on Feb 04, 2026Accuray Incorporated announced that they will report Q2, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 04, 2026
お知らせ • Jan 21Accuray Incorporated Announces Resignation of Sandeep Chalke as Senior Vice President and Chief Commercial Officer, Effective March 31, 2026Accuray Incorporated announced that on January 15, 2026, Sandeep Chalke provided notice of his intent to resign from his position as Senior Vice President and Chief Commercial Officer of the company, with the resignation effective on March 31, 2026. Mr. Chalke’s resignation was not a result of any disagreement with the Company or the Board of Directors of the Company, or any matter relating to the Company’s operations, policies or practices.
お知らせ • Jan 01Accuray Incorporated Announces Retirement of Byron C. Scott as Class III Director and Including All Committees, Effective December 31, 2025On December 27, 2025, Byron C. Scott, a Class II director of Accuray Incorporated, informed the company’s Board of Directors that he will retire from the Board, including all committees of the Board on which he sits, effective December 31, 2025. The decision by Mr. Scott to retire from the Board is not due to any disagreement with the Company or the Board, or any matter relating to the Company’s operations, policies or practices.
New Risk • Dec 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$14m net loss in 2 years). Market cap is less than US$100m (US$97.0m market cap).
分析記事 • Dec 20Accuray (NASDAQ:ARAY) May Have Issues Allocating Its CapitalIf you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...
分析記事 • Dec 02Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% PoundingThe Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...
分析記事 • Nov 27Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Nov 14Consensus EPS estimates fall by 929%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$475.2m to US$466.7m. Losses expected to increase from US$0.035 per share to US$0.36. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$4.75 to US$3.88. Share price fell 11% to US$1.04 over the past week.
Breakeven Date Change • Nov 14Forecast breakeven date pushed back to 2028The 2 analysts covering Accuray previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of US$8.60m in 2028. Average annual earnings growth of 42% is required to achieve expected profit on schedule.
Reported Earnings • Nov 06First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.18 loss per share (further deteriorated from US$0.039 loss in 1Q 2025). Revenue: US$93.9m (down 7.5% from 1Q 2025). Net loss: US$21.7m (loss widened 448% from 1Q 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Nov 06Accuray Incorporated Reaffirms Earnings Guidance for the Fiscal Year 2026Accuray Incorporated reaffirmed earnings guidance for the fiscal year 2026. The company expects total net revenue in the range of $471 million to $485 million.
お知らせ • Oct 29Accuray Incorporated to Report Q1, 2026 Results on Nov 05, 2025Accuray Incorporated announced that they will report Q1, 2026 results on Nov 05, 2025
お知らせ • Oct 21+ 1 more updateAccuray Incorporated Announces Executive ChangesAccuray Incorporated announced that on October 20, 2025, the board appointed Stephen La Neve as President effective as of October 20, 2025. Mr. La Neve was also appointed to the Board as a Class III director with his initial term ending at the Company’s 2027 annual meeting of stockholders. Mr. La Neve will succeed Suzanne Winter, the Company’s President who has resigned from her position as President and has resigned as a member of the Board, effective October 19, 2025. Ms. Winter will continue to serve as an advisor through November 30, 2025 to provide an orderly transition. Mr. La Neve, 66, most recently served as President of the Trauma and Joint Reconstruction business unit of Globus Medical Inc. and, previously, Globus Medical Japan K.K., a provider of musculoskeletal device solutions, from 2019 to 2024. From 2015 to 2019, Mr. La Neve was CEO of Bone Biologics Corporation, a medical device company focused on bone regeneration. He also served as a member of the board of directors of Bone Biologics Corporation until December 2022. Prior to that, Mr. La Neve served as CEO of Life Science Enterprises Inc., an early-stage biomaterials company spun out from ETEX Corporation, from 2014 to 2015, and CEO of ETEX Corporation, an advanced biomaterials company, from 2014 until Zimmer Holdings Inc. acquired the business of ETEX Holdings Inc. late in 2014. Prior to that role, Mr. La Neve was CEO and a member of the board of directors at SkelRegen, LLC, Global President of Becton Dickinson Preanalytical Systems, Global President of Medtronic Spine and Biologics Inc., as well as President of Medtronic Japan. Early in his career, Mr. La Neve served in various commercial roles for three diagnostics companies: Becton Dickinson, Roche and EM Diagnostic Systems, domestically and internationally. He has served as a board member for several healthcare companies in the medical device and diagnostic segments, currently including Insight Medbotics, a company developing MRI guided robotics for interventional oncology. Mr. La Neve holds a B.S. in Health Planning and Administration from the Pennsylvania State University and an MBA from West Chester University. He is a member of Omicron Delta Epsilon, an international honor society recognizing academic excellence and achievements in economics.
分析記事 • Oct 10Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share PriceAccuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...
お知らせ • Oct 08Accuray Incorporated Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® SystemAccuray Incorporated announced that 5D Clinics has treated the first patients in the city of Melbourne, Australia, using the CyberKnife S7™ System. 5D Clinics and joint venture partner Icon Group will open and operate CyberKnife System centers across Australia, with the goal of making it easier for cancer patients to obtain precision robotic stereotactic body radiation therapy (SBRT) and stereotactic radio surgery (SRS) treatments closer to home. With an initial focus on the East Coast of Australia, the new center in Melbourne is the first to be managed by the J. The number of new cancer cases diagnosed in Australia is projected to grow from 212,332 in 2022 to 318,285 in 20451, a nearly 50% increase. The rise in patient diagnoses reinforces the need for innovative new treatment options, such as the CyberKnife System, that can effectively manage the disease while improving the care journey and its impact on patients' quality of life. The CyberKnife S7™ System combines speed, precision, and artificial intelligence (AI) to track and automatically adapt for movement during treatment, delivering the radiation dose directly to the target anywhere in the body. The precision and accuracy of the system enables medical teams to deliver very high doses of radiation in a few days versus conventional fractionation which often require 30-40 sessions. The entire CyberKnife System procedure is typically completed in just 1 to 5 out-patient sessions, making radiation treatments delivered with sub-millimeter precision and accuracy an option for people unable to travel a month or more for care. alphaXRT is the exclusive distributor, installer and training partner for the Accuray CyberKnife and TomoTherapy® platform portfolios in Australasia. In close cooperation with the Accuray global team, 5D Clinics and Icon Group, they supported the entire CyberKnife System installation process through the first patient treatment, and will provide ongoing service and assistance.
お知らせ • Oct 02Accuray Incorporated, Annual General Meeting, Nov 13, 2025Accuray Incorporated, Annual General Meeting, Nov 13, 2025.
お知らせ • Sep 26Accuray Incorporated Launches All-In-One Radiotherapy Solution with Advanced Capabilities Designed to Set A New Standard in Cancer CareAccuray Incorporated announced that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™? Solution. Initially for the U.S. market, the new Accuray technology is not just a system, it's a solution, comprised of a comprehensive tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy. The Accuray Stellar solution, a configuration of the Radixact®? Treatment Delivery System, will be featured at Accuray booth #525 during the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California, September 28 - 30, 2025. Meeting attendees are invited to attend the U.S. unveiling at the company's booth on September 28, at 11:30 am PT. To broaden the reach of transformative cancer care, Accuray Stellar easily integrates with the company's proprietary software and hardware solutions -- and vendor partner technologies -- expanding the range of available radiation delivery options and streamlining the treatment workflow for each patient. With Accuray Stellar, clinicians have access to a solution capable of the full range of delivery modalities, from image-guided radiation therapy (IMRT) to stereotactic body radiation therapy (SBRT) treatments and surface-guided ration therapy (SGRT), to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow radiation. Accuray Stellar provides a unique option for accurately delivering radiation while correcting for changes in the size or shape of the tumor, and patient or tumor movement, that can occur while patients undergo care. The solution offers a versatile and simplified path to adaptive radiotherapy developed to provide the foundation for adaptive care that can evolve with each patient's needs. The adaptive suite ranges from real-time motion tracking and correction, with Synchrony®? technology, to offline adaptive protocols featuring PreciseART®?, as well as an online-adaptive ready interface (a prerequisite for OART), providing the foundation for adaptive care that evolves with each patient's needs. Medical care teams can also leverage one of the company's latest innovations, Adapt LTE powered by Accuray Cenos, only available on Accuray Stellar.
Price Target Changed • Sep 23Price target decreased by 8.1% to US$4.75Down from US$5.17, the current price target is an average from 2 analysts. New target price is 176% above last closing price of US$1.72. Stock is down 2.8% over the past year. The company is forecast to post a net loss per share of US$0.035 next year compared to a net loss per share of US$0.015 last year.
お知らせ • Aug 23Accuray Incorporated Announces Management ResignationOn August 19, 2025, Robert C. Kill, a Class I director of Accuray Incorporated (the Company"), informed the Company's Board of Directors (the Board") of his intention not to stand for re-election at the Company's 2025 annual meeting of stockholders to be held in November 2025 (the Annual Meeting"). Mr. Kill will continue to serve as a director and member of the Compensation Committee of the Board until the conclusion of the Annual Meeting. The decision by Mr. Kill to not stand for re-election is not due to any disagreement with the Company or the Board, or any matter relating to the Company's operations, policies or practices. On August 19, 2025, Jesse Chew provided the Company with notice of his intent to resign from his position as Senior Vice President, Chief Legal Officer and Corporate Secretary of the Company, which resignation will be effective on September 19, 2025. Mr. Chew has agreed to consult with the Company through December 31, 2025, subject to terms to be agreed upon between the Company and Mr. Chew. Mr. Chew's resignation was not a result of any disagreement with the Company or the Board, or any matter relating to the Company's operations, policies or practices.
Major Estimate Revision • Aug 20Consensus estimates of losses per share improve by 36%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$445.1m to US$475.8m. EPS estimate increased from -US$0.047 per share to -US$0.03 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target up from US$5.17 to US$5.50. Share price was steady at US$1.51 over the past week.
Reported Earnings • Aug 14Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$0.015 loss per share (improved from US$0.16 loss in FY 2024). Revenue: US$458.5m (up 2.7% from FY 2024). Net loss: US$1.59m (loss narrowed 90% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 3.8% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Aug 14Accuray Incorporated Provides Earnings Guidance for Fiscal Year Ending June 30, 2026Accuray Incorporated provided earnings guidance for fiscal year ending June 30, 2026. For the year, the company expects total net revenue in the range of $471 million to $485 million. GAAP net loss expected to be $12,000,000 to $8,000,000.
分析記事 • Aug 13Returns At Accuray (NASDAQ:ARAY) Are On The Way UpIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
お知らせ • Jul 31Accuray Incorporated to Report Q4, 2025 Results on Aug 13, 2025Accuray Incorporated announced that they will report Q4, 2025 results on Aug 13, 2025
分析記事 • Jun 28Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...
Recent Insider Transactions • Jun 18Independent Chairman of the Board recently bought US$62k worth of stockOn the 13th of June, Joseph Whitters bought around 50k shares on-market at roughly US$1.25 per share. This transaction amounted to 8.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.
Price Target Changed • Jun 12Price target decreased by 8.1% to US$5.17Down from US$5.63, the current price target is an average from 3 analysts. New target price is 313% above last closing price of US$1.25. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.0033 next year compared to a net loss per share of US$0.16 last year.
お知らせ • Jun 06Accuray Incorporated Appoints Steven F. Mayer to Its BoardAccuray Incorporated has entered into a governance agreement with TCW Asset Management Company LLC, which provides for the appointment of one director to Accuray's Board of Directors. TCW has designated, and Accuray has appointed, Steven F. Mayer to its Board. Mr. Mayer serves as Chairman of the Operations Advisory Council and senior advisor to the private credit group of TCW. Previously, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, and Co-Head of Global Private Equity and Chairman of the Investment Committee of Cerberus Capital Management, L.P., a private investment firm with approximately $60 billion of capital under management. He has extensive governance experience, having served as a member of the Boards of Directors of more than 30 other public and private companies spanning a range of industries, including medical technology and biotherapeutics.
Price Target Changed • May 07Price target decreased by 8.2% to US$5.63Down from US$6.13, the current price target is an average from 4 analysts. New target price is 314% above last closing price of US$1.36. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.0075 next year compared to a net loss per share of US$0.16 last year.
お知らせ • May 02Accuray Incorporated Provides Earnings Guidance for the Fourth Quarter of 2025Accuray Incorporated provided earnings guidance for the fourth quarter of 2025. For the quarter, the company expects revenues to be in the range of $121 million to $129 million.
New Risk • May 01New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Large one-off items impacting financial results.
お知らせ • May 01Accuray Incorporated Provides Earnings Guidance for the Full Year 2025Accuray Incorporated provided earnings guidance for the full year 2025. For the period, the company's Total revenue is expected in the range of $452 millionto $460 million.
Board Change • May 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Director Rob Kill was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 17Accuray Incorporated to Report Q3, 2025 Results on Apr 30, 2025Accuray Incorporated announced that they will report Q3, 2025 results on Apr 30, 2025
分析記事 • Apr 04Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share PriceWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
お知らせ • Apr 03Accuray Incorporated Announces New Data on the Clinical Use of the CyberKnife SystemAccuray Incorporated announced that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States1. The studies, involving the delivery of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), were presented at the recent 2025 Radiosurgery Society (RSS) Scientific Meeting in Tucson, Arizona. SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destruction) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony® adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion. The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tumors like vestibular schwannoma or managing complex conditions such as spinal metastases and trigeminal neuralgia, the common thread is the need for precise, highly targeted radiation delivery -- a hallmark of the CyberKnife System; These new data not only reinforce its value in central nervous system treatments but also add to the growing body of evidence supporting its role in improving both the quality and longevity of patients' lives; 25-year data were reported for patients in a single institution study retrospectively evaluating SRS for the treatment of VS (also known as acoustic neuroma) using the CyberKnife System. A non-cancerous, usually slow-growing brain tumor, VS can cause hearing loss, ringing in the ear, and dizziness or loss of balance. Pain improved or disappeared in 90% of those evaluated and only 3% developed paresthesia - a sensation of tingling, "pins and needs" or numbness - considered bothersome. Data indicate radiosurgery provides an option for a patient population that may have limited choices because health issues preclude surgery or they are unresponsive to medication4. An evaluation of SRS for occipital condyle metastasis (OCM) using the CyberKnife system found the treatment offers significant pain relief, excellent local control rates and improvement in neurological symptoms. A 93.8% local tumor control rate was achieved over three years.
分析記事 • Mar 11Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price DropAccuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...
Reported Earnings • Feb 06Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.025 (up from US$0.098 loss in 2Q 2024). Revenue: US$116.2m (up 8.3% from 2Q 2024). Net income: US$2.54m (up US$12.2m from 2Q 2024). Profit margin: 2.2% (up from net loss in 2Q 2024). Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 06Accuray Incorporated Raises Earnings Guidance for the Year 2025Accuray Incorporated raising earnings guidance for the year 2025. For the year, the company expects total revenue is expected in the range of $463 million to $475 million.
お知らせ • Jan 23Accuray Incorporated to Report Q2, 2025 Results on Feb 05, 2025Accuray Incorporated announced that they will report Q2, 2025 results on Feb 05, 2025
お知らせ • Jan 21Accuray Incorporated Appoints Leonel Peralta as Senior Vice President, Chief Operations Officer, Effective February 3, 2025Accuray Incorporated announced that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has a proven work history in driving growth while improving productivity and bringing more than 25 years of leadership experience in supply chain, business process improvement, and manufacturing optimization. Most recently, Leonel was Vice President, Head of Global Operations for the ultrasound division at Siemens Healthineers where he led the transformation of supply chain processes, the manufacturing footprint and the organizational structure, for the ultrasound business unit within the company. Prior to this, Leonel held executive management positions at Medtronic Diabetes, Hill-Rom (Baxter), KCI Medical (3M), and GE Healthcare. Under his leadership his teams executed corporate growth and financial objectives, significantly reduced inventory levels, and transformed sourcing and supply chain operations.
分析記事 • Jan 18Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For GrowthAccuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...
お知らせ • Jan 15Accuray Incorporated Announces China National Medical Products Administration Approval of Radixact SynC and CyberKnife S7 SystemsAccuray Incorporated announced that the company's Radixact SynC System and CyberKnife S7 System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform and the introduction of the Radixact SynC System marks the first approval in the country for the ClearRT kVCT imaging and Synchrony real-time adaptive delivery technology on the Radixact System. The Radixact SynC and CyberKnife S7 Systems are designed to improve the radiation treatment experience while making high precision care available for more patients. Radixact SynC System: Cancer Treatment that Revolves Around the Patient: The Radixact SynC System's helical design enables the delivery of precise doses of radiation continuously from multiple 360-degree rotations around the patient, providing greater control of the radiation dose so it conforms precisely to the tumor and minimizes dose to healthy tissue. The Radixact SynC System is currently the only helical delivery device in China with Synchrony real-time target tracking and correction technology. The addition of Synchrony to the Radixact System is designed to facilitate more precise delivery of radiation to tumors that move as a result of bodily processes or patient movement. The Accuray proprietary Synchrony technology is unique in using image guidance during radiation treatment delivery to detect motion and automatically adapt and synchronize the radiation beam in real-time with the movement of the target. ClearRT is a helical kVCT fan-beam integrated imaging solution for the Radixact System, providing clinicians with an option for easily, quickly and cost effectively acquiring diagnostic-like quality CT images. These images enable high confidence in the patient set-up and registration steps that form the basis of radiation therapy treatment delivery and monitoring and are key to the successful treatment of organ-confined tumors, locally advanced tumors and metastatic tumors. The CyberKnife S7 System: Robotic Precision that Makes Treatment Possible in just 1 to 5 Out-Patient Sessions: The new generation CyberKnife platform delivers the extremely precise radiation treatments clinicians have come to expect with the system, combined with the speed they need to support their busy practices. The CyberKnife S7 System is a robotic, non-invasive radiosurgery device capable of treating cancerous and benign tumors throughout the body with sub-millimetric accuracy in as little as 15 minutes, enabling medical care teams to provide highly precise radiation treatments to more patients, every day. The precision and accuracy of the CyberKnife System enables clinical teams to deliver ultra-hypofractionated radiation therapy ? very high doses of precisely targeted radiation are delivered in a few days versus conventional fractionation where treatments often require 30-40 sessions. The entire procedure with the CyberKnife System is typically completed in just 1 to 5 out-patient sessions, enabling those people who are unable to travel a month or more for care to receive radiation therapy treatments.
Seeking Alpha • Jan 07Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking Alpha
分析記事 • Dec 19Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Dec 14Accuray Incorporated Announces the Departure of Michael Hoge as Senior Vice President, Global Operations, Effective January 6, 2025On December 6, 2024, Accuray Incorporated and Michael Hoge, the company’s Senior Vice President, Global Operations, mutually agreed to terms pursuant to which Mr. Hoge will depart the Company as an employee effective January 6, 2025. Mr. Hoge’s departure is not the result of any dispute or disagreement with the Company, its board of directors, or its management, or any matter relating to the Company’s operations, policies or practices. The Company has initiated a comprehensive search process to identify Mr. Hoge’s successor.
Seeking Alpha • Dec 05Accuray Incorporated: Cheap, But With CaveatsSummary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking Alpha
お知らせ • Nov 28Accuray Incorporated Approves to Appoint Michael Murphy as the Principal Accounting Officer, Effective December 2, 2024Accuray Incorporated approved the appointed Michael Murphy, 45, as the Company’s principal accounting officer, effective December 2, 2024. Mr. Murphy joined the Company in October 2024 as Vice President, Corporate Controller. Previously, from February 2024 to October 2024, he served as Vice President, Chief Accounting Officer and Treasury at Duluth Trading Company, an American workwear and accessories company, where he also served as Interim Chief Financial Officer, Vice President and Chief Accounting Officer from September 2023 to February 2024, Vice President and Chief Accounting Officer from September 2019 to August 2023 and Corporate Controller from December 2018 to September 2019. Prior to that, he served as Chief Accounting Officer at First Business Financial Services Inc., a financial services company, from September 2015 to December 2018. Mr. Murphy began his career at KPMG LLP. Mr. Murphy received a Bachelor of Business Administration, Accounting and Finance as well as a Master of Accountancy, both from the University of Wisconsin-Madison.
お知らせ • Nov 08Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025Accuray Incorporated raised financial guidance for the fiscal year ending June 30, 2025. For the year, the company’s total revenue is expected in the range of $462 million to $472 million; GAAP net loss expected in the range of $4,500,000 to $2,500,000.
お知らせ • Oct 24Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024Accuray Incorporated announced that they will report Q1, 2025 results on Nov 06, 2024
お知らせ • Oct 15Accuray Incorporated Announces CEO ChangesAccuray Incorporated announced that, effective as of October 15, 2024, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer. Sandeep Chalke, who has served as interim CEO during Ms. Winter's absence, will continue in his position as Senior Vice President and Chief Commercial Officer.
お知らせ • Oct 07Accuray Incorporated, Annual General Meeting, Nov 21, 2024Accuray Incorporated, Annual General Meeting, Nov 21, 2024.
お知らせ • Sep 17Accuray Incorporated announced delayed annual 10-K filingOn 09/16/2024, Accuray Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 04+ 1 more updateAccuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of AbsenceAccuray Incorporated announced that President Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an Executive Committee of the Board of Directors, consisting of Joseph Whitters, Chairman of the Accuray Board, and Anne Le Grand, Chair of the Science and Technology Committee, that will advise Mr. Chalke in his interim capacity. Mr. Chalke joined Accuray in May 2022 bringing more than 30 years of medical device expertise in commercialization, business development and operations. In his role at Accuray, he has responsibility for the global commercial function, including the organization's sales, service and operations teams.
Seeking Alpha • Aug 18Accuray Remains A Perpetual 'Next Year Is Our Year' StorySummary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking Alpha
Breakeven Date Change • Aug 16Forecast breakeven date pushed back to 2026The 4 analysts covering Accuray previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 73% to 2025. The company is expected to make a profit of US$12.4m in 2026. Average annual earnings growth of 137% is required to achieve expected profit on schedule.
New Risk • Aug 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.6% increase in shares outstanding).
Reported Earnings • Aug 15Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.16 loss per share (further deteriorated from US$0.098 loss in FY 2023). Revenue: US$446.6m (flat on FY 2023). Net loss: US$15.5m (loss widened 68% from FY 2023). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 15Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025Accuray Incorporated provided earnings guidance for the fiscal year 2025. For the year, total revenue is expected in the range of $460 million to $470 million.
分析記事 • Aug 13Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching RevenuesAccuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...
お知らせ • Aug 01Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024Accuray Incorporated announced that they will report Q4, 2024 results on Aug 14, 2024
お知らせ • Jun 15Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products AdministrationAccuray Incorporated announced that the registration dossier for the AccurayPrecision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China. The Accuray Precision TPS was developed to facilitate the creation and adaptation of precise treatment plans in less time. The planning solution enables clinicians to routinely incorporate modifications to treatment planning into the course of treatment to account for changes in tumor size, shape and location – as well as subtle changes in the location of organs and other healthy tissue – thereby increasing treatment precision. The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue. The system is designed to enable medical care teams to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.
Breakeven Date Change • Jun 06Forecast breakeven date pushed back to 2026The 4 analysts covering Accuray previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$15.5m in 2026. Average annual earnings growth of 123% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jun 02Independent Chairman of the Board recently bought US$156k worth of stockOn the 29th of May, Joseph Whitters bought around 100k shares on-market at roughly US$1.56 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.
分析記事 • May 21Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price DropTo the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...
お知らせ • May 11Accuray Incorporated Announces Executive Changes, Effective May 17, 2024On May 6, 2024, Gina Corradetti provided Accuray Incorporated with notice of her intent to resign from her position as Chief Accounting Officer and principal accounting officer, which resignation will be effective May 17, 2024, to pursue other opportunities. On May 9, 2024, the Company’s Board of Directors appointed Ali Pervaiz, the Company’s Senior Vice President, Chief Financial Officer, to serve as the Company’s interim principal accounting officer, effective May 17, 2024 until a permanent successor is appointed. Mr. Pervaiz, age 44, will continue to serve as the Company’s Senior Vice President and Chief Financial Officer, a position he has held since May 2022. Previously, Mr. Pervaiz served as the Company’s Vice President, Global Commercial Operations beginning August 2020. Prior to joining the Company, Mr. Pervaiz was with General Electric Healthcare (“GE Healthcare”), a global medical technology, pharmaceutical diagnostics, and digital solutions innovator and subsidiary of General Electric Company, for over 15 years in senior financial and operating leadership roles, most recently as Executive – Margin Growth PMO Leader focused on Margin Expansion for the Global Imaging business from September 2018 to January 2020 and Executive – Advance Leader focused on Commercial Strategy & Finance Transformation from January 2017 to September 2018. During his tenure at GE Healthcare, Mr. Pervaiz, who was selected for and graduated from the Corporate Audit Staff program, also previously held business unit Chief Financial officer roles at GE Healthcare for the US Commercial Diagnostic Imaging Equipment and US Commercial Life Support Solutions businesses. Mr. Pervaiz received an M.B.A. from the University of Chicago Booth School of Business with focus on finance and operations, an M.S. in healthcare technologies management from the Medical College of Wisconsin and a B.S. from Marquette University.
分析記事 • May 04Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest ResultsIt's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...
Price Target Changed • May 03Price target decreased by 11% to US$7.75Down from US$8.75, the current price target is an average from 4 analysts. New target price is 378% above last closing price of US$1.62. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.098 last year.
分析記事 • May 03Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...
お知らせ • May 03Accuray Incorporated Provides Earnings Guidance for the Year 2024Accuray Incorporated provided earnings guidance for the year 2024. The company is adjusting its guidance for fiscal year 2024 as follows: Total revenue is expected in the range of $432 million to $437 million.
Reported Earnings • May 02Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: US$0.064 loss per share (down from US$0.006 profit in 3Q 2023). Revenue: US$101.1m (down 14% from 3Q 2023). Net loss: US$6.34m (down US$6.94m from profit in 3Q 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • May 02Now 35% undervalued after recent price dropOver the last 90 days, the stock has fallen 38% to US$1.53. The fair value is estimated to be US$2.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Apr 26Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024Accuray Incorporated announced that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife®? and Radixact®? platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland. Accuray is a wellness focused organization, taking into account the patient's health and well-being throughout their treatment when prioritizing product enhancements. The solutions featured at ESTRO represent a few of the most recent innovations introduced over a 30 year history of invention and disruption that has led to new standards in care for the radiation therapy industry. The company invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases-- while making commonly treatable cases even easier--to meet the full spectrum of patient needs.
お知らせ • Apr 19Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024Accuray Incorporated announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on May 01, 2024
Seeking Alpha • Apr 07Accuray Getting Very Little Love Ahead Of A Coming Revenue RampSummary Despite management guidance that points to significant revenue acceleration in the next two quarters, Accuray shares have languished. Market skepticism can be tied in part to the company's track record - despite multiple efforts to improve its portfolio and go-to-market strategy, market share growth has been very modest. The company's entry into China's Type B market could be its last best chance to change the narrative - meaningful share in a $600M/year market should be transformative. Accuray faces tough competition from Varian and Elekta, but is focusing on upgrading its installed base, targeting selective vault share gain opportunities, and pursuing value-based opportunities in emerging markets. Accuray shares should trade closer to $4-$6, but Accuray must deliver on the potential of the Chinese market and establish new, higher, expectations for growth and margins. Read the full article on Seeking Alpha
お知らせ • Mar 26Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife SystemAccuray Incorporated announced that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy - supporting the system's versatility and value to medical care teams. The CyberKnife System enables treatment of prostate cancer using a form of radiation therapy called stereotactic body radiation therapy (SBRT) - very precise, high doses of radiation are delivered over a shorter duration than traditional treatments. The system's precision enables clinicians to confidently treat the prostate gland, which is situated near the sensitive bladder and rectum, with SBRT. CyberKnife Platform for Prostate Cancer: The CyberKnife platform offers an effective treatment option for prostate tumors in 4-5 sessions, compared to conventional radiation therapy that usually requires approximately 30-40 sessions over 8-10 weeks. Data presented at the RSS meeting showed its ability to: Effectively treat high-risk disease while preserving quality of life. Study authors concluded, "At the 3-year follow-up mark, favorable biochemical control was achieved, and patients had largely recovered to near baseline urinary and bowel function. These findings underscore the potential of SBRT as a convenient treatment option for high-risk prostate cancer, offering promising outcomes and preserving patient quality of life. Provide a viable option with "a low incidence of short-term genitourinary (GU) and gastrointestinal (GI) toxicities" for reirradiation of locally recurrent prostate cancer. The prostate gland can move unpredictably throughout the course of treatment. In fact, the prostate has been documented to move as much as 10 mm in as little as 30 seconds due to normal patient bodily functions – such as filling of the bladder, gas in the bowel, or even slight patient movement during the procedure making the ability to track, detect and correct for motion critically important. The CyberKnife System, using advanced imaging and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery, with the Accuray proprietary Synchrony® technology, can track the tumor and continually verify its position, automatically correcting and adapting the radiation beam position for even the slightest movement. For example, if the prostate moves during treatment the CyberKnife® System detects this movement and synchronizes the treatment delivery beam to the tumor's new position in real-time.
New Risk • Feb 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Significant insider selling over the past 3 months (US$433k sold).
分析記事 • Feb 03Is Accuray (NASDAQ:ARAY) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Feb 02Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: US$0.098 loss per share (further deteriorated from US$0.02 loss in 2Q 2023). Revenue: US$107.2m (down 6.6% from 2Q 2023). Net loss: US$9.62m (loss widened 413% from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Breakeven Date Change • Feb 01The 3 analysts covering Accuray previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 45% to 2024. The company is expected to make a profit of US$14.8m in 2025. Average annual earnings growth of 1.1% is required to achieve expected profit on schedule.
